Females and Males of Reproductive Potential: Fertility: Based on animal studies, Tecentriq may impair fertility in females of reproductive potential while receiving treatment (see Pharmacology: Toxicology: Nonclinical Safety: Impairment of Fertility under Actions).
Contraception: Female patients of childbearing potential should use highly effective contraception and take active measures to avoid pregnancy while undergoing Tecentriq treatment and for at least 5 months after the last dose (see General under Precautions, and Pharmacology: Toxicology: Nonclinical Safety: Reproductive Toxicity under Actions).
Pregnancy: There are no clinical studies of Tecentriq in pregnant women. Tecentriq is not recommended during pregnancy unless the potential benefit for the mother outweighs the potential risk to the fetus (see Pharmacology: Toxicology: Nonclinical Safety: Reproductive Toxicity under Actions).
Labor and Delivery: The use of Tecentriq during labor and delivery has not been established.
Lactation: It is not known whether Tecentriq is excreted in human breast milk. No studies have been conducted to assess the impact of Tecentriq on milk production or its presence in breast milk. As the potential for harm to the nursing infant is unknown, a decision must be made to either discontinue breast-feeding or discontinue Tecentriq therapy.